TICKERNERD
Menu
ASNDASNDHealthcare · Biotechnology

ASND Stock Forecast: Ascendis Pharma A/S Price Predictions for 2026-2027

Last close, 22 Oct 2026
$243
+1.71% on the day

The 21 Wall Street analysts covering Ascendis Pharma A/S hold a median 12-month price target of $305 — +25.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 22 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$15.4B
Ticker Nerd rank
85/ 100
Median analyst target
$305
Analysts covering
21
Revenue$339.3M+114.7% y/y
Operating income$220.5M
Net income$207.0M
Free cash flow$270.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.2%
1M
+2.3%
YTD
+14.0%
1Y
+19.9%
From 52W high
−12.3%
From 52W low
+24.0%
$196
$277
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ASND stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ascendis Pharma A/S on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
85/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Volatility
97
Value
97
Growth
92
Issuance
78
Momentum
65
Revisions
58
Accruals
13
Size
12

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ASND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350Jan 26Apr 26Jul 26Oct 26ASNDHigh $350Median $305Low $262

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
21 Buy0 Hold0 Sell
Low $262Median $305High $350

The green dot is the last close — the median target sits +25.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Oct 2026UBSAssumesBuy$307 → $269
25 Sept 2026Cantor FitzgeraldReiteratesOverweight$300
25 Sept 2026Cantor FitzgeraldReiteratesOverweight—
15 Sept 2026Raymond JamesDowngradeOutperform—
2 Sept 2026OppenheimerMaintainsOutperform—
1 Sept 2026Morgan StanleyMaintainsOverweight—
1 Sept 2026WedbushReiteratesOutperform—
31 Aug 2026B of A SecuritiesMaintainsBuy—
31 Aug 2026HC Wainwright & Co.MaintainsBuy—
31 Aug 2026JefferiesMaintainsBuy—
31 Aug 2026StifelMaintainsBuy—
27 Aug 2026HC Wainwright & Co.InitiatesBuy—
19 Aug 2026BMO CapitalInitiatesOutperform—
14 Aug 2026BarclaysMaintainsOverweight—
14 Aug 2026RBC CapitalMaintainsOutperform—
14 Aug 2026TD CowenMaintainsBuy—
23 July 2026Morgan StanleyMaintainsOverweight—
7 July 2026RBC CapitalMaintainsOutperform—
19 May 2026CitigroupInitiatesBuy—
15 May 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ASND appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

ASND vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Ascendis Pharma A/S returned +19.9% against +15.6% for the S&P 500, dividends included.

ASND vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130Jan 26Apr 26Jul 26Oct 26ASNDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ASND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+6.4%
Analysts raising
1
Analysts cutting
1
Fundamentals

Ascendis Pharma A/S (ASND) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
18.3×

Cheaper than 40% of US stocks

Price / sales
15.0×

Cheaper than 10% of US stocks

Price / book
9.7×

Cheaper than 9% of US stocks

EV / EBITDA
57.0×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
114.7%

Higher than 93% of US stocks

Earnings growth (YoY)
114.7%

Higher than 85% of US stocks

Gross margin
91.8%

Higher than 97% of US stocks

Operating margin
65.0%

Higher than 99% of US stocks

Net margin
70.8%

Higher than 98% of US stocks

Returns & dividend
Return on equity
118.8%

Higher than 97% of US stocks

Return on assets
9.6%

Higher than 91% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ascendis Pharma A/S (ASND) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ascendis Pharma A/S has a market value of $15.4B and an enterprise value of $16.9B.

  • Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 114.7% year on year.

  • Net income over the same four quarters: $741.8M, a 70.8% net margin.

  • Diluted earnings per share, trailing twelve months: $11.03.

  • Free cash flow in the twelve months to 30 June 2026: $335.1M.

  • Ascendis Pharma A/S spent $103.4M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 65.7M.

  • Trailing P/E: 18.3×; forward P/E: 22.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ascendis Pharma A/S employs 1,189 people — $881K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

ASND vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ASNDAscendis Pharma A/S$15.4B85
HALOHalozyme Therapeutics, Inc.$14.1B98
JAZZJazz Pharmaceuticals Plc$13.5B98
BBIOBridgeBio Pharma, Inc.$13.2B67
EXELExelixis, Inc.$17.0B98
SMMTSummit Therapeutics, Inc.$12.4B29
CORTCorcept Therapeutics, Inc.$11.5B71

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ascendis Pharma A/S — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ASND news & analysis

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

GlobeNewsWire · 16 Oct 2026positive

Ascendis Pharma said the EMA’s CHMP issued a positive opinion recommending EU marketing authorization for once-weekly TransCon CNP (navepegritide) for children aged two and older with achondroplasia whose epiphyses are not closed. The European Commission’s decision on the application is expected in Q4 2026.

Why it matters — The opinion is a regulatory milestone for Ascendis Pharma’s application to market the treatment in the EU.

FAQ

Frequently asked questions about ASND stock

What is the ASND stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Ascendis Pharma A/S have a median 12-month price target of $305, with estimates ranging from $262 to $350. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ASND stock a buy right now?

Of the 21 analysts covering Ascendis Pharma A/S, 21 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ascendis Pharma A/S 85 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ASND?

As at 22 Oct 2026, Ascendis Pharma A/S ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will ASND stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +25.4% from the last close, and Ticker Nerd's factor model ranks Ascendis Pharma A/S 85 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ASND stock forecast for 2030?

No analyst covering Ascendis Pharma A/S publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $262 to $350 over the next 12 months.

How has ASND stock performed over the past year?

Ascendis Pharma A/S returned +19.9% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs.

What is the latest news on ASND?

The most recent item we track (GlobeNewsWire, 16 Oct 2026): "Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children". Ascendis Pharma said the EMA’s CHMP issued a positive opinion recommending EU marketing authorization for once-weekly TransCon CNP (navepegritide) for children aged two and older with achondroplasia whose epiphyses are not closed. The European Commission’s decision on the application is expected in Q4 2026.

Company

About Ascendis Pharma A/S.

Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs. Its current portfolio includes marketed products for growth hormone deficiency and chronic hypoparathyroidism, along with clinical-stage programs in endocrinology rare disease and oncology. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates across Europe and the United States, combining research, development, and commercialization capabilities to support patients, physicians, and healthcare systems in specialized therapeutic areas.

CEO Mr. Jan Moller Mikkelsen · 1,189 employees · Denmark · https://ascendispharma.com